What MATINAS BIOPHARMA does

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Bedminster, New Jersey, that develops therapeutics for fungal and bacterial infections using its proprietary Lipid Nano-Crystal (LNC) drug delivery platform. The LNC platform nano-encapsulates small molecules, oligonucleotides, vaccines, peptides, and proteins in lipid nanocrystals to enable safe, intracellular, oral delivery of compounds that would otherwise require intravenous administration. The company's clinical-stage pipeline includes MAT2203, an oral formulation of amphotericin B for invasive fungal infections (cryptococcal meningitis, invasive aspergillosis, mucor infections, chronic refractory mucocutaneous candidiasis); MAT9001 (branded LYPDISO), a prescription-only EPA/DPA omega-3 composition for cardiovascular and metabolic conditions; and MAT2501, an oral amikacin formulation for nontuberculous mycobacterial (NTM) lung disease supported by Cystic Fibrosis Foundation funding.

The company is pre-revenue with no products available for sale; all three drug candidates remain in development. MAT2203 has received FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations for cryptococcal meningitis, and its Phase 2 EnACT trial met its primary survival endpoint. MAT9001 demonstrated approximately 6-fold higher EPA bioavailability, median triglyceride reduction of -33.2% versus -10.5% for Vascepa (p<0.0001), and statistically significant reductions in PCSK9 versus Vascepa in head-to-head studies. Business development is conducted via investor and scientific conferences, with the company exploring strategic alternatives and partnership arrangements following the termination of MAT2203 partnership negotiations in October 2024. Capital is raised through public offerings and direct/convertible preferred stock issuances.

Name

MATINAS BIOPHARMA

Legal name

Matinas BioPharma Holdings, Inc.

Website

https://matinasbiopharma.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Matinas BioPharma is a clinical-stage biopharmaceutical company developing oral formulations of amphotericin B, omega-3, and amikacin using its proprietary Lipid Nano-Crystal (LNC) delivery platform to treat invasive fungal and bacterial infections.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (lipid nanocrystal drug delivery)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Lipid nanocrystal drug delivery
• Antifungal therapeutics development
• Oral amphotericin B formulation
• Prescription omega-3 therapy
• Intracellular drug delivery platform

Headquarters

HQ city

Tarpon Springs

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Product Development Revenue: Pre-revenue clinical stage biopharmaceutical company. All product candidates (MAT2203, MAT9001, MAT2501) are in development stage and not available for sale. Revenue generation expected upon regulatory approval and commercialization of drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Matinas BioPharma is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary Lipid Nano-Crystal (LNC) drug delivery platform. Its lead candidate MAT2203 is an oral formulation of amphotericin B for invasive fungal infections; MAT9001 (LYPDISO) is a prescription omega-3 composition for cardiovascular and metabolic conditions; and MAT2501 is an oral amikacin formulation for nontuberculous mycobacterial lung disease in cystic fibrosis. All candidates are in development and not yet available for sale.

Product overview

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing therapies using its proprietary Lipid Nano-Crystal (LNC) platform delivery technology. The company's product portfolio includes: MAT2203, an oral amphotericin B formulation for invasive fungal infections (lead anti-infective product candidate in Phase 2/3 development); MAT9001/LYPDISO, an omega-3 fatty acid composition for cardiovascular and metabolic diseases; and MAT2501, an oral amikacin formulation for NTM lung disease. The LNC platform enables intracellular delivery of small molecules and oligonucleotides, potentially making drugs safer, more tolerable, and orally bioavailable.

Differentiator

Problem solved

Functional benefit

Products and services

• Lipid Nano-Crystal (LNC) Platform Proprietary lipid nanocrystal drug delivery platform that nano-encapsulates small molecules, oligonucleotides, vaccines, peptides, proteins, and gene editing technologies in lipid nano-crystals (cochleate-based), enabling safe, intracellular, oral delivery of therapeutics that would otherwise require IV administration.
• MAT2203 (Oral Amphotericin B) Oral formulation of amphotericin B using the LNC platform, developed for the treatment of invasive fungal infections including cryptococcal meningitis, invasive aspergillosis, mucor infections, and chronic refractory mucocutaneous candidiasis. Designed to retain fungicidal activity of amphotericin B with lower risk of renal toxicity and anemia than IV amphotericin B. Has received FDA QIDP, Fast Track, and Orphan Drug Designations for cryptococcal meningitis / cryptococcosis.
• MAT9001 (LYPDISO) Prescription-only next-generation omega-3 fatty acid composition comprising EPA and DPA, developed for cardiovascular and metabolic conditions including severe hypertriglyceridemia, dyslipidemia, and cardiovascular disease risk reduction. Demonstrated approximately 6-fold higher EPA AUC and Cmax vs Vascepa, with median -33.2% triglyceride reduction vs -10.5% for Vascepa (p<0.0001) and statistically significant reductions in PCSK9, total cholesterol, VLDL-cholesterol, and non-HDL cholesterol.
• MAT2501 (Oral Amikacin) Oral LNC formulation of amikacin, a broad-spectrum aminoglycoside antibiotic, in development for the treatment of nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis. Designed to provide an oral alternative to IV amikacin with improved tolerability.

Quantifiable outcome

• Phase 2 EnACT study met primary endpoint with robust survival in HIV patients with cryptococcal meningitis
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and strategic.

• National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 7 December 2020Collaboration to evaluate oral formulations of Gilead's antiviral remdesivir using Matinas' LNC platform delivery technology. NIAID is part of the National Institutes of Health.
• Gilead SciencesstrategicTechnology or Integration · 7 December 2020Partner company whose antiviral drug remdesivir is being evaluated in oral formulations using Matinas' LNC platform technology in collaboration with NIAID.
• Top Global Pharmaceutical Company (Undisclosed)strategicTechnology or Integration · 10 January 2019Research evaluation agreement to evaluate synergistic effects of Matinas' LNC platform delivery technology with the partner's nucleic acid polymer technology. Matinas will formulate select oligonucleotides using its proprietary LNC platform for testing in preclinical studies. Partner identity and financial terms are confidential.
• National Institute of Neurological Disorders and Stroke (NINDS) / NIHcoreStrategic or Co-development Partner · 9 July 2018Research collaboration with NINDS, part of the National Institutes of Health, focused on developing a novel HIV therapy combining antisense oligonucleotides (ASO) with Matinas' LNC delivery technology. Studies being conducted at NIH in Bethesda, MD under direction of Dr. Avindra Nath. The goal is to inhibit Tat/viral mRNA translation to address viral replication, chronic inflammation, and neurological complications in HIV patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MatinasBio
• Facebookfacebook.com/matinasbiopharma
• LinkedInlinkedin.com/company/matinas-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MATINAS BIOPHARMA